The European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) has adopted a negative opinion, recommending the refusal of the marketing authorisation for the medicinal product masitinib (Masiviera), intended for the treatment of advanced inoperable pancreatic cancer. Read more
here.
No comments:
Post a Comment